Thus, results suggest that the FTO inhibitor acts explicitly on the pancreatic cancer cells that overexpress FTO and remain insensitive to the normal HPDE cells with low FTO expression (Figure 1). The gene discussed is FTO; the disease is familial pancreatic carcinoma.